Přihlásit se Zaregistrujte se zdarma

Vlastnictví managementu společnosti Alexion Pharmaceuticals

Jaká je hodnota metriky Vlastnictví managementu společnosti Alexion Pharmaceuticals?

Hodnota metriky Vlastnictví managementu společnosti Alexion Pharmaceuticals Inc. je 0.34%

Jaká je definice metriky Vlastnictví managementu?



Vlastnictví managementu (Insider Ownership) je poměr akcií vlastněných akcionáři v rámci firmy (akcionáři, kteří vlastní více než 5% společnosti nebo ve funkci ředitele či vedoucího odddělení) a veškerých vydaných akcií.

A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.

A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.

Vlastnictví managementu společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Alexion Pharmaceuticals

Čemu se věnuje společnost Alexion Pharmaceuticals?

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

Firmy s metrikou vlastnictví managementu podobnou společnosti Alexion Pharmaceuticals